Cambridge Trust Co. raised its holdings in shares of UnitedHealth Group Inc (NYSE:UNH) by 0.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 151,413 shares of the healthcare conglomerate’s stock after purchasing an additional 370 shares during the period. UnitedHealth Group comprises about 2.0% of Cambridge Trust Co.’s portfolio, making the stock its 10th largest holding. Cambridge Trust Co.’s holdings in UnitedHealth Group were worth $29,655,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in UNH. Blue Chip Partners Inc. bought a new stake in UnitedHealth Group during the second quarter valued at $110,000. Kings Point Capital Management grew its position in shares of UnitedHealth Group by 27.9% during the first quarter. Kings Point Capital Management now owns 687 shares of the healthcare conglomerate’s stock worth $113,000 after acquiring an additional 150 shares during the last quarter. Bruderman Asset Management LLC bought a new position in shares of UnitedHealth Group during the second quarter worth about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of UnitedHealth Group by 433.3% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock worth $119,000 after acquiring an additional 520 shares during the last quarter. Finally, BDO Wealth Advisors LLC bought a new position in shares of UnitedHealth Group during the second quarter worth about $121,000. Hedge funds and other institutional investors own 86.01% of the company’s stock.
In other UnitedHealth Group news, CEO Larry C. Renfro sold 22,598 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $221.75, for a total value of $5,011,106.50. Following the completion of the sale, the chief executive officer now directly owns 195,314 shares of the company’s stock, valued at approximately $43,310,879.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas E. Roos sold 975 shares of the company’s stock in a transaction dated Thursday, October 19th. The shares were sold at an average price of $205.47, for a total transaction of $200,333.25. Following the completion of the sale, the insider now directly owns 24,630 shares of the company’s stock, valued at $5,060,726.10. The disclosure for this sale can be found here. Insiders sold a total of 34,630 shares of company stock valued at $7,669,416 in the last quarter. 0.89% of the stock is currently owned by insiders.
UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.09. The firm had revenue of $50.32 billion during the quarter, compared to analyst estimates of $50.38 billion. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. UnitedHealth Group’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.17 EPS. equities analysts forecast that UnitedHealth Group Inc will post 9.99 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Friday, December 1st were given a $0.75 dividend. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $3.00 dividend on an annualized basis and a yield of 1.34%. UnitedHealth Group’s dividend payout ratio is presently 34.09%.
Several research firms have recently commented on UNH. Goldman Sachs Group began coverage on shares of UnitedHealth Group in a research report on Wednesday. They set a “buy” rating and a $269.00 price target for the company. Wells Fargo & Co restated an “outperform” rating and set a $245.00 price target (up previously from $230.00) on shares of UnitedHealth Group in a research report on Wednesday, November 29th. Leerink Swann restated an “outperform” rating on shares of UnitedHealth Group in a research report on Friday, December 1st. Citigroup upped their price target on shares of UnitedHealth Group from $213.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Finally, BMO Capital Markets began coverage on shares of UnitedHealth Group in a research report on Monday, October 16th. They set an “outperform” rating and a $250.00 price target for the company. Three analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $226.74.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/01/04/unitedhealth-group-inc-unh-holdings-increased-by-cambridge-trust-co.html.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
What are top analysts saying about UnitedHealth Group? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for UnitedHealth Group and related companies.